DrugPatentWatch Database Preview
Profile for Serbia Patent: 20120339
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
US Patent Family Members and Approved Drugs for Serbia Patent: 20120339
US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
---|---|---|---|---|
Start Trial | Apr 27, 2027 | Celgene | REVLIMID | lenalidomide |
Start Trial | Oct 7, 2023 | Celgene | REVLIMID | lenalidomide |
Start Trial | Nov 24, 2024 | Celgene | REVLIMID | lenalidomide |
Start Trial | Oct 7, 2023 | Celgene | REVLIMID | lenalidomide |
Start Trial | Jun 17, 2025 | Celgene | POMALYST | pomalidomide |
Start Trial | Oct 7, 2023 | Celgene | REVLIMID | lenalidomide |
>US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |